Loading
Everything OnCo dates to 1969: 10 entries, 5 landmarks, 3 approvals, 1 company founded and 1 journal founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
10 dated entries in OnCo fall in 1969: 5 landmarks, 3 approvals, 1 company founded and 1 journal founded.
Of those, 10 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Cytarabine approved for acute leukaemia; 7+3 established 1973
Remission induction in acute non-lymphocytic leukaemia; ALL; blast-phase CML; intrathecal therapy of meningeal leukaemia
Stage III and IV Hodgkin disease in combination (MOPP)
The history entries editors wrote on cancer records: the dated turning points of each disease.
Vestibular schwannoma (acoustic neuroma)
Newly diagnosed multiple myeloma, transplant-ineligible
Wilms tumour (nephroblastoma). Cooperative-group model that raised survival from ~30% to ~90% over five trials.
Rosai-Dorfman-Destombes disease
Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. Destombes had reported cases in 1965.
The founded year on company records.
Palo Alto, CA
The founded year on journal records.
Wiley